Gerresheimer buys Vedat to get bigger in South America

pharmafile | March 28, 2011 | News story | Manufacturing and Production Brazil, Gerresheimer, packaging 

Glass and plastics packaging specialist Gerresheimer has acquired Brazilian company Vedat in a major push into the South American pharmaceutical packaging market.

Vedat makes plastic pharmaceutical packaging components, particularly closures, and has operations in more than 20 countries around the world, with production facilities in Brazil and Mexico.

Gerresheimer already manufactures pharmaceutical plastic packaging and medical plastic systems for the South American market at three plants in Brazil and one plant in Argentina, acquired along with its purchase of Spanish packaging company EDP in 2008.

Last year, the German company set up a production facility in Brazil for insulin pen systems as part of a long-term strategic collaboration with Novo Nordisk, which has a plant making insulin active pharmaceutical ingredients (APIs) nearby.

“Expanding in emerging markets is a key component of our growth strategy”, commented Uwe Rohrhoff, Gerresheimer’s chief executive.

Acquiring Vedat strengthens Gerresheimer’s position in the South American pharmaceutical primary packaging market  and “perfectly fits our strategy of doubling our sales in the emerging markets from 100 million euros to 200 million euros by 2013”, he added.

Vedat, headquartered in Sao Paulo, had sales of 106 million Brazilian reals (roughly 45 million euros) in 2010 and employs approximately 450 people. Its product portfolio of plastic closures, PET bottles and other plastic containers is complementary to Gerresheimer’s own product offering, according to Rohrhoff.

“Now that we have the combination of bottles and closures, we can provide a fully comprehensive range of products and services to our South American pharmaceutical customers on a one-stop-shop basis”, he said.

Phil Taylor

 

Related Content

Kintor’s COVID-19 treatment reduces mortality by 92%

Kintor Pharmaceutical’s Proxalutamide treatment has been proven to reduce risk of mortality from COVID-19 by …

shutter

Amryt’s Lojuxta approved in Brazil to reduce cholesterol in homozygous familial hypercholesterolaemia patients

Brazil’s National Health Surveillance Agency (ANVISA) has moved to authorise Amryt’s Lojuxta (lomitapide) in the …

flu_vaccination_grippe_5115654021

Sinovac COVID-19 trial suspended in Brazil due to severe adverse event

Brazil’s health regulator Anvisa has suspended a clinical trial for China’s Sinovac coronavirus vaccine due …

Latest content